by the amount of model thresholds passed) while Figure shows some examples of compounds predicted to result in favorable drug loading properties, passing at least five of the eight thresholds at 6 g/L drug feed (including LC≥30 or LE≥60). Besides many taxanes that are structurally closely related to paclitaxel making up a relatively large amount of data points of our formulation database, a variety of compounds across different therapeutic fields are predicted to result in high loading, including e.g. macrolide antibiotics, analgesics and anticancer agents. Structures reminiscent of curcumin are also found, containing di-or trimethoxyphenyl moieties or hydroxyphenyl groups, like many (iso-)flavons. The hits also include multiple compounds in clinical trials: ladarixin (CXCR1/2 inhibitor) and resminostat (HDAC inhibitor) are considered for combination therapies against pancreatic cancer . IOWH-032 is a CFTR inhibitor that also supresses SARS-CoV-2 replication and GS-6620 is a pre-cursor of the antiviral drug remdesivir and assessed as treatment against the Ebola virus . These compounds might be tested in future experimental studies to extend the available data for QSPR modeling and establish pOx/pOzi-based drug delivery systems for more therapeutic fields.